A randomized, open label, two-arm, three period crossover bioavailability study comparing two new nilotinib tablet formulations to an established nilotinib capsule formulation in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2012
At a glance
- Drugs Nilotinib (Primary)
- Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Novartis
- 23 Apr 2012 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
- 19 Jan 2007 New trial record.